Platinum (II) complexes and their nanoformulations: preparation, characterisation and cytotoxicity

Abstract

Development of novel drugs or drug delivery systems has attracted much attention of researchers. In this study, we aimed to prepare 2 new Pt(II) complexes with thiosemicarbazone and their nanoformulations for cancer treatment application. Pt(II)-camphor thiosemicarbazone/ P1 and Pt(II)-camphor 4-phenyl thiosemicarbazone/P2) were successfully prepared and structurally confirmed by MS, IR, 1H-NMR, UV-vis spectroscopies and thermal analysis. From the complexes, 2 PLGA-based nanoformulations (nP1 and nP2) were synthesised with the average size of 50 nm by emulsification/evaporation method and investigated for their toxicity against Hep-G2, LU-1 and RD cancer cell lines. The results show that the Pt(II) complexes and their nanoformulations were potential for chemotherapy.

The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives

“…The inability of researchers to bypass these problems can be linked to the incomplete unraveling of the mechanism of action of cisplatin, which is unknown in many ways. In recent years, [58][59][60][61] drug-delivery strategies have been developed to ameliorate the selectivity and, therefore, the systemic effects, but it will be necessary to implement and differentiate molecular targets to reverse therapeutic failure risks. As far as platinum(IV) complexes are concerned, the mechanism of activation and the consequent reduction products that form remain to be clarified.…”